BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 7531222)

  • 1. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis.
    Lee WR; Hanks GE; Schultheiss TE; Corn BW; Hunt MA
    J Clin Oncol; 1995 Feb; 13(2):464-9. PubMed ID: 7531222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group.
    Lattanzi JP; Hanlon AL; Hanks GE
    Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):569-73. PubMed ID: 9231681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
    Lee WR; Hanlon AL; Hanks GE
    J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy.
    Bonin SR; Hanlon AL; Lee WR; Movsas B; al-Saleem TI; Hanks GE
    Cancer; 1997 Jan; 79(1):75-80. PubMed ID: 8988729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
    Anderson PR; Hanlon AL; Patchefsky A; Al-Saleem T; Hanks GE
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1087-92. PubMed ID: 9719119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer.
    Pinover WH; Hanlon AL; Horwitz EM; Hanks GE
    Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):649-54. PubMed ID: 10837947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.
    Pollack A; Smith LG; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):507-12. PubMed ID: 10974469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose response in prostate cancer with 8-12 years' follow-up.
    Hanks GE; Hanlon AL; Epstein B; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):427-35. PubMed ID: 12243818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy.
    Anderson PR; Hanlon AL; Horwitz E; Pinover W; Hanks GE
    Cancer; 2000 Dec; 89(12):2565-9. PubMed ID: 11135217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
    Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy.
    Kupelian PA; Elshaikh M; Reddy CA; Zippe C; Klein EA
    J Clin Oncol; 2002 Aug; 20(16):3376-85. PubMed ID: 12177097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 1989 patterns of care study for prostate cancer: five-year outcomes.
    Chuba PJ; Moughan J; Forman JD; Owen J; Hanks G
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):325-34. PubMed ID: 11380218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biochemical control after conformal, 3 dimensional radiotherapy of prostatic carcinoma].
    Geinitz H; Zimmermann F; von Wedel E; Thamm R; Busch R; Feldmann HJ; Molls M
    Strahlenther Onkol; 2002 Jul; 178(7):369-77. PubMed ID: 12163991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
    Anderson PR; Hanlon AL; Movsas B; Hanks GE
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1025-30. PubMed ID: 9392540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 100-day PSA: usefulness as surrogate end point for biochemical disease-free survival after definitive radiotherapy of prostate cancer.
    Johnstone PA; Williams SR; Riffenburgh RH
    Prostate Cancer Prostatic Dis; 2004; 7(3):263-7. PubMed ID: 15289811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.